

Resonance Health appoints Jason Loveridge (PhD) to Board

Resonance Health is pleased to announce the appointment of Dr Loveridge to the Board as non-executive director, effective immediately.

Dr Loveridge, based in Europe, has been working with young, growth orientated businesses in the biotech and medtech industries for over 20 years. As an active venture investor he has established a lengthy track record of successful participation in European, US and Israeli based healthcare companies. Based in Europe he also has considerable international experience at board level and a particular interest in business development, mergers & acquisitions.

Dr Loveridge's current directorships include: Warambi Sari (owner and Executive Director) providing investment funds, management and advice for privately held and publicly traded companies within the life science and medical device sector; Parvulus Suiss SA and its parent company, a Swiss medical device company in the cardiovascular space; JDS BioPharma Limited, an Australian investment vehicle; and Anaconda SAS, a French anti-viral drug discovery company.

Resonance Health is delighted Dr Loveridge has joined the Board bringing a wealth of experience and an international perspective.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne

Managing Director

T: +61 8 9286 5300

E: lizad@resonancehealth.com

Naomi Haydari

Company Secretary

T: +61 8 9286 5300

E: naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.